Literature DB >> 26171005

Screening and identification of apolipoprotein A-I as a potential hepatoblastoma biomarker in children, excluding inflammatory factors.

Wei Zhao1, Juan Li2, Yilin Zhang3, Pengfei Gao1, Junjie Zhang1, Fei Guo1, Jiekai Yu4, Shu Zheng4, Jiaxiang Wang1.   

Abstract

The aim of the present study was to identify a child hepatoblastoma serum biomarker that is unaffected by inflammatory factors, with the ultimate aim of finding an effective method for the early diagnosis of hepatoblastoma. The magnetic bead-based weak cation exchange chromatography technique was used to process serum harvested from 30 children with hepatoblastoma, 20 children with systemic inflammatory response syndrome (SIRS) and 20 healthy children. Proteins differentially expressed in SIRS were excluded from consideration as biomarkers for hepatoblastoma. Proteins differentially expressed in hepatoblastoma and healthy controls were screened using surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS). Target proteins were purified by SDS-PAGE, and matrix-assisted laser desorption/ionization (MALDI)-TOF-MS was used to determine their amino acid sequences. Protein matches were searched in the SwissProt database. Quantitative polymerase chain reaction (qPCR) and ELISA were employed to confirm the expression of target proteins. Following screening to exclude inflammatory factors, SELDI-TOF-MS revealed a protein with a mass-to-charge ratio of 9,348 Da that was expressed at significantly lower levels in the serum of children with hepatoblastoma compared with healthy controls (P<0.01). Sequence analysis identified this protein as apolipoprotein A-1 (Apo A-I). qPCR and ELISA confirmed that the expression of Apo A-I mRNA and protein were significantly lower in children with hepatoblastoma compared with healthy controls (P<0.05). These results indicate that Apo A-I is a non-inflammatory protein marker for hepatoblastoma with the potential for use in early diagnosis of hepatoblastoma. In addition, the present study demonstrates the feasibility of proteomic screening for the identification of proteins that can serve as markers for a specific tumor.

Entities:  

Keywords:  Apo A-I; MALDI-TOF-MS; biomarker; hepatoblastoma; proteomics

Year:  2015        PMID: 26171005      PMCID: PMC4487141          DOI: 10.3892/ol.2015.3207

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  32 in total

Review 1.  [Proteic profiling SELDI-TOF and breast cancer: clinical potential applications].

Authors:  Anthony Gonçalves; François Bertucci; Daniel Birnbaum; Jean-Paul Borg
Journal:  Med Sci (Paris)       Date:  2007-03       Impact factor: 0.818

Review 2.  Apolipoprotein A-I: structure-function relationships.

Authors:  P G Frank; Y L Marcel
Journal:  J Lipid Res       Date:  2000-06       Impact factor: 5.922

3.  Proteomic studies of early-stage and advanced ovarian cancer patients.

Authors:  Jing Wang; Xiaowei Zhang; Xiaohui Ge; Hongyan Guo; Guangwu Xiong; Yan Zhu
Journal:  Gynecol Oncol       Date:  2008-08-15       Impact factor: 5.482

Review 4.  Proteomics for discovery of candidate colorectal cancer biomarkers.

Authors:  Paula Alvarez-Chaver; Olalla Otero-Estévez; María Páez de la Cadena; Francisco J Rodríguez-Berrocal; Vicenta S Martínez-Zorzano
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

Review 5.  Proteomic approaches for serum biomarker discovery in cancer.

Authors:  Priyanka Maurya; Paula Meleady; Paul Dowling; Martin Clynes
Journal:  Anticancer Res       Date:  2007 May-Jun       Impact factor: 2.480

6.  Immunotherapy of tumors with recombinant adenovirus encoding macrophage inflammatory protein 3beta induces tumor-specific immune response in immunocompetent tumor-bearing mice.

Authors:  Jian-mei Hou; Xia Zhao; Ling Tian; Gang Li; Ru Zhang; Bing Yao; Hong-xin Deng; Jin-liang Yang; Yu-quan Wei
Journal:  Acta Pharmacol Sin       Date:  2009-03       Impact factor: 6.150

7.  High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma.

Authors:  Tsunenori Kondo; Fumio Ito; Hayakazu Nakazawa; Shigeru Horita; Yukinari Osaka; Hiroshi Toma
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

Review 8.  Blood markers for early detection of colorectal cancer: a systematic review.

Authors:  Sabrina Hundt; Ulrike Haug; Hermann Brenner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-10       Impact factor: 4.254

Review 9.  The molecular biology of human apoA-I, apoA-II, apoC-II and apoB.

Authors:  S W Law; K J Lackner; S S Fojo; A Hospattankar; J C Monge; H B Brewer
Journal:  Adv Exp Med Biol       Date:  1986       Impact factor: 2.622

10.  Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance.

Authors:  Tingting Du; Gang Yuan; Muxun Zhang; Xinrong Zhou; Xingxing Sun; Xuefeng Yu
Journal:  Cardiovasc Diabetol       Date:  2014-10-20       Impact factor: 9.951

View more
  4 in total

1.  Maternal Preeclampsia and Odds of Childhood Cancers in Offspring: A California Statewide Case-Control Study.

Authors:  Xiaoqing Xu; Beate Ritz; Myles Cockburn; Christina Lombardi; Julia E Heck
Journal:  Paediatr Perinat Epidemiol       Date:  2017-01-26       Impact factor: 3.980

2.  The Preoperative Peripheral Blood Monocyte Count Is Associated with Liver Metastasis and Overall Survival in Colorectal Cancer Patients.

Authors:  Shidong Hu; Zhenyu Zou; Hao Li; Guijun Zou; Zhao Li; Jian Xu; Lingde Wang; Xiaohui Du
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

3.  Development of a MALDI MS-based platform for early detection of acute kidney injury.

Authors:  Emma Carrick; Jill Vanmassenhove; Griet Glorieux; Jochen Metzger; Mohammed Dakna; Martin Pejchinovski; Vera Jankowski; Bahareh Mansoorian; Holger Husi; William Mullen; Harald Mischak; Raymond Vanholder; Wim Van Biesen
Journal:  Proteomics Clin Appl       Date:  2016-05-17       Impact factor: 3.494

4.  Circulating D-dimer level correlates with disease characteristics in hepatoblastoma patients.

Authors:  BinBin Zhang; GongBao Liu; XiangQi Liu; Shan Zheng; Kuiran Dong; Rui Dong
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.